Patients with advanced serous ovarian cancer, Figo stage III and IV. Malignant neoplasm of ovary
Conditions
Interventions
Intervention 1: For first group, at first daycombination ofgemcitabin (1000 mg per square meter on days 1 and 8 IV during 30 minutes) and cisplatin (75 mg per square meter, IV) are administrated. This
Treatment - Drugs
For first group, at first daycombination ofgemcitabin (1000 mg per square meter on days 1 and 8 IV during 30 minutes) and cisplatin (75 mg per square meter, IV) are administrated. This protocol can be
For group 2, combination of carboplatin (carboplatin at an area under the concentration-time curve (AUC) of 5-6 mg/mL/min IV over 1 hour and paclitaxel (175 mg per square meter IV over 3 hours) on t
Sponsors
Women's Reproductive Health Research Center, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with advanced serous ovarian cancer Figo Stage III and IV; the volume of ascites, that is determined by ultrasound or CT scan, more than 500cc
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CA-125 levels. Timepoint: before surgery. Method of measurement: Lab measurement.;The volume of residual tumor. Timepoint: During surgery. Method of measurement: Clinical judgment.;The volume of ascites. Timepoint: During surgery. Method of measurement: Clinical estimation.;Bleeding. Timepoint: During surgery. Method of measurement: Clinical estimation.;Surgery duration. Timepoint: During surgery. Method of measurement: During surgery.;Death during surgery. Timepoint: During surgery. Method of measurement: observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Wound infection, dehicsence, nausea, vomiting,diarrhea, illeus, intestinal obstruction, hospital stay. Timepoint: 24 h after surgery. Method of measurement: observation, ultrasonography, CT-scan.;Ascites collection. Timepoint: 24 hours after surgery. Method of measurement: observation, ultrasonography, CT-scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactManizheh Sayyah-Melli
Tabriz University of Medical Sciences
Outcome results
None listed